ArticleOncology and therapy2016

A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.

Wafaa Hassan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.